Minnesota's cannabis regulators have published one of the largest looks yet at how people with autism fare in a state medical cannabis program.
The Office of Cannabis Management (OCM) study analyzed data from 1,811 adult and pediatric patients qualified for autism spectrum disorder between Aug. 1, 2018, and July 31, 2024. It drew on enrollment records, purchases and symptom ratings logged at each purchase.
Anxiety was the most common symptom, with 88.3% reporting moderate to severe scores. Among them, 57% saw at least a 30% drop within four months of their first purchase, and about one-third (34.3%) kept that improvement for at least four more months. For depression, 63.4% reported a meaningful drop and 42.9% maintained it. Results for children and adults were similar.
The fine print matters: there was no control or placebo group, and the study didn't account for other treatments, so it can't show cannabis caused the improvements. OCM says more research is needed and recommends talking with a medical professional about dosing before starting.
Minnesota is required by law to study its medical patients' experiences, and autism has been a qualifying condition since 2018.
What it means for travelers: This is medical research, not a reason to self-treat. Visiting adults shopping legally in Minnesota should start low, go slow, and lean on the state's safer-use guide.






